The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options. "With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life," Zydus Lifesciences said in a regulatory filing.
